Myelosuppression is a painless condition in which depletion of blood cells, results in anemia, neutropenia and thrombocytopenia. Myelosuppression is bone marrow suppression. The blood cells that are formed in the bone marrow are found to be reduced in myelosuppression. Myelosuppression is the most common side effect of the cancer chemotherapy treatment. Thus, it is commonly found in cancer patients. These conditions leads to fatigue, excessive bleeding and increased risk of infections. Myelosuppression is usually a temporary condition but the irreversible damage to the bone marrow may cause permanent myelosuppression.Myelosuppression is commonly managed by reducing the dose or modification of chemotherapy that allows the recovery of hematopoietic activity.

Chemotherapy Induced Myelosuppression Treatment Market: Drivers and Restraints

The major factor driving the growth of chemotherapy induced myelosuppression market is increasing incidence of cancer. According to World Health Organization, approximately 8.2 Mn deaths were reported due to cancer in the year 2012. Also, it is predicted that annual cancer cases will rise from 14 Mn to 22 Mn in next two decades. In addition, it is stated by National Cancer Institute that there were approximately 1,660,290 cases reported in the U.S. in 2013. Increasing incidences of cancer increases the risk of myelosuppression and hence is anticipated to drive market growth during the forecast period. However, less number of commercially available drugs for the treatment of myelosuppression may restrain the market growth.

Request free sample Report: http://www.futuremarketinsights.com/reports/sample/rep-gb-1364

Chemotherapy Induced Myelosuppression Treatment Market: Segmentation

The global chemotherapy induced myelosuppression treatment market has been classified on the basis of product type, end use and geography.

Based on product type, the global chemotherapy induced myelosuppression treatment market is divided into following:

• Granulocyte Colony-Stimulating Factor (G-CSF)
• Recombinant human erythropoietin erythropoiesis-stimulating agents (ESAs)
• Granulocyte-macrophage colony-stimulating factor (GM-CSF)
• Antibiotics
• Thrombopoietic Agents
• Peripheral Blood Stem Cells

Based on end user type, the global chemotherapy induced myelosuppression treatment market is divided into following:

• Hospitals
• Clinics
• Cancer rehabilitation centers

Chemotherapy Induced Myelosuppression Treatment Market: Overview

Due to the availability of variety of chemotherapeutic agents for cancer treatment, the risk of myelosuppression is expected to increase significantly. Thus, pharmaceutical and biopharmaceutical industries are focusing on the research and development of myelosuppression treatment. The Granulocyte Colony-Stimulating Factor (G-CSF) and Granulocyte-macrophage colony-stimulating factor (GM-CSF) segments are projected to collectively hold a major share owing to the patient’s effective response by these therapies. The first line of treatment for chemotherapy induced myelosuppression is reducing the dose of chemotherapeutic agents though the chemotherapy is continued for the treatment of cancer.

Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1364

Chemotherapy Induced Myelosuppression Treatment Market: Regional Overview

Geographically, the global chemotherapy induced myelosuppression treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. U.S. is the largest chemotherapy induced myelosuppression market while Europe is considered as the second largest market for chemotherapy induced myelosuppression. Large patient base with increasing geriatric population in these regions drives the growth of this market. The market of chemotherapy induced myelosuppression in APAC is expected to grow at a rapid pace owing to a rise in total number of newly diagnosed patient population in this region. According to World Health Organization, 60% of the world’s total annual cases of cancer occur in Africa, Asia and Latin America which is anticipated to boost market growth in the regions.

Chemotherapy Induced Myelosuppression Treatment Market: Key Players

Some of the key players in chemotherapy induced myelosuppression market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Biocon, Emcure Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., and Abbott.

Browse full report: http://www.futuremarketinsights.com/reports/chemotherapy-induced-myelosuppression-treatment-market